Founded in 2008, Stemcentrx combines state-of-the-art research and GMP manufacturing capabilities. This has allowed us to advance from target discovery in our laboratory to treating patients in clinical trials at an accelerated pace. We are investigating many of the largest and most lethal cancers through our proprietary platforms that identify cancer stem cells and discover novel targets,and we engineer and manufacture antibodies and antibody drug conjugates for those targets.
Stemcentrx has five investigational drugs in human clinical trials. As single agents, three have generated objective clinical responses in patients with small cell lung cancer, triple-negative breast cancer, ovarian cancer, and peritoneal cancer, and two have recently begun phase I clinical trials. Beyond these five clinical programs, we have a pipeline of additional novel targets to address other major cancer types.

On April 28, 2016 Stemcentrx was acquired by AbbVie for $5.8 billion.

Parent Company
South San Francisco, US
StemCentRx was founded in 2008 and is headquartered in South San Francisco, US

StemCentRx Office Locations

StemCentRx has an office in South San Francisco
South San Francisco, US (HQ)
450 E Jamie Ct

StemCentRx Data and Metrics

StemCentRx Summary

In total, StemCentRx had raised $473 m. StemCentRx is a subsidiary of AbbVie

StemCentRx Online and Social Media Presence

StemCentRx News and Updates

StemCentRx Company Life and Culture

You may also be interested in